Global Urticaria Drugs Market 2024-2028

The urticaria drugs market is forecasted to grow by USD 1.66 bn during 2023-2028, accelerating at a CAGR of 11.64% during the forecast period. The report on the urticaria drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of urticaria, guidelines for management of urticaria patients, and increasing approval of new drugs for urticaria.

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	10.38%
CAGR	11.64%
Incremental Value	$1.66bn

Technavio's urticaria drugs market is segmented as below:

By Application

Acute urticaria
Chronic urticaria

By Type

Antihistamines
Anti-inflammatory agents
Sulfones
Biologics

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the emergence of biologics to treat urticaria as one of the prime reasons driving the urticaria drugs market growth during the next few years. Also, technological and clinical research advancements and increasing research funding for urticaria will lead to sizable demand in the market.

The report on the urticaria drugs market covers the following areas:

Urticaria drugs market sizing
Urticaria drugs market forecast
Urticaria drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading urticaria drugs market vendors that include Allakos Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Meiji Holdings Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, TerSera Therapeutics LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the urticaria drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR73292

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global urticaria drugs market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global urticaria drugs market 2018 - 2022 ($ billion)
4.2 Application Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)
4.3 Type Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Application

6.1 Market segments
Exhibit 30: Chart on Application - Market share 2023-2028 (%)
Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
6.2 Comparison by Application
Exhibit 32: Chart on Comparison by Application
Exhibit 33: Data Table on Comparison by Application
6.3 Acute urticaria - Market size and forecast 2023-2028
Exhibit 34: Chart on Acute urticaria - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Acute urticaria - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Acute urticaria - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Acute urticaria - Year-over-year growth 2023-2028 (%)
6.4 Chronic urticaria - Market size and forecast 2023-2028
Exhibit 38: Chart on Chronic urticaria - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Chronic urticaria - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Chronic urticaria - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Chronic urticaria - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Application
Exhibit 42: Market opportunity by Application ($ billion)
Exhibit 43: Data Table on Market opportunity by Application ($ billion)

7 Market Segmentation by Type

7.1 Market segments
Exhibit 44: Chart on Type - Market share 2023-2028 (%)
Exhibit 45: Data Table on Type - Market share 2023-2028 (%)
7.2 Comparison by Type
Exhibit 46: Chart on Comparison by Type
Exhibit 47: Data Table on Comparison by Type
7.3 Antihistamines - Market size and forecast 2023-2028
Exhibit 48: Chart on Antihistamines - Market size and forecast 2023-2028 ($ billion)
Exhibit 49: Data Table on Antihistamines - Market size and forecast 2023-2028 ($ billion)
Exhibit 50: Chart on Antihistamines - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Antihistamines - Year-over-year growth 2023-2028 (%)
7.4 Anti-inflammatory agents - Market size and forecast 2023-2028
Exhibit 52: Chart on Anti-inflammatory agents - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Anti-inflammatory agents - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Anti-inflammatory agents - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Anti-inflammatory agents - Year-over-year growth 2023-2028 (%)
7.5 Sulfones - Market size and forecast 2023-2028
Exhibit 56: Chart on Sulfones - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Sulfones - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Sulfones - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Sulfones - Year-over-year growth 2023-2028 (%)
7.6 Biologics - Market size and forecast 2023-2028
Exhibit 60: Chart on Biologics - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Biologics - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Biologics - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Biologics - Year-over-year growth 2023-2028 (%)
7.7 Market opportunity by Type
Exhibit 64: Market opportunity by Type ($ billion)
Exhibit 65: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 Canada - Market size and forecast 2023-2028
Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Allakos Inc.
Exhibit 115: Allakos Inc. - Overview
Exhibit 116: Allakos Inc. - Product / Service
Exhibit 117: Allakos Inc. - Key offerings
12.4 Amneal Pharmaceuticals Inc.
Exhibit 118: Amneal Pharmaceuticals Inc. - Overview
Exhibit 119: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 120: Amneal Pharmaceuticals Inc. - Key news
Exhibit 121: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 122: Amneal Pharmaceuticals Inc. - Segment focus
12.5 Aurobindo Pharma Ltd.
Exhibit 123: Aurobindo Pharma Ltd. - Overview
Exhibit 124: Aurobindo Pharma Ltd. - Product / Service
Exhibit 125: Aurobindo Pharma Ltd. - Key offerings
12.6 Bayer AG
Exhibit 126: Bayer AG - Overview
Exhibit 127: Bayer AG - Business segments
Exhibit 128: Bayer AG - Key news
Exhibit 129: Bayer AG - Key offerings
Exhibit 130: Bayer AG - Segment focus
12.7 F. Hoffmann La Roche Ltd.
Exhibit 131: F. Hoffmann La Roche Ltd. - Overview
Exhibit 132: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 133: F. Hoffmann La Roche Ltd. - Key news
Exhibit 134: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 135: F. Hoffmann La Roche Ltd. - Segment focus
12.8 GlaxoSmithKline Plc
Exhibit 136: GlaxoSmithKline Plc - Overview
Exhibit 137: GlaxoSmithKline Plc - Business segments
Exhibit 138: GlaxoSmithKline Plc - Key news
Exhibit 139: GlaxoSmithKline Plc - Key offerings
Exhibit 140: GlaxoSmithKline Plc - Segment focus
12.9 Johnson and Johnson
Exhibit 141: Johnson and Johnson - Overview
Exhibit 142: Johnson and Johnson - Business segments
Exhibit 143: Johnson and Johnson - Key news
Exhibit 144: Johnson and Johnson - Key offerings
Exhibit 145: Johnson and Johnson - Segment focus
12.10 Meiji Holdings Co. Ltd.
Exhibit 146: Meiji Holdings Co. Ltd. - Overview
Exhibit 147: Meiji Holdings Co. Ltd. - Business segments
Exhibit 148: Meiji Holdings Co. Ltd. - Key news
Exhibit 149: Meiji Holdings Co. Ltd. - Key offerings
Exhibit 150: Meiji Holdings Co. Ltd. - Segment focus
12.11 Novartis AG
Exhibit 151: Novartis AG - Overview
Exhibit 152: Novartis AG - Business segments
Exhibit 153: Novartis AG - Key offerings
Exhibit 154: Novartis AG - Segment focus
12.12 Otsuka Holdings Co. Ltd.
Exhibit 155: Otsuka Holdings Co. Ltd. - Overview
Exhibit 156: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 157: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 158: Otsuka Holdings Co. Ltd. - Segment focus
12.13 Pfizer Inc.
Exhibit 159: Pfizer Inc. - Overview
Exhibit 160: Pfizer Inc. - Product / Service
Exhibit 161: Pfizer Inc. - Key news
Exhibit 162: Pfizer Inc. - Key offerings
12.14 Sanofi SA
Exhibit 163: Sanofi SA - Overview
Exhibit 164: Sanofi SA - Business segments
Exhibit 165: Sanofi SA - Key news
Exhibit 166: Sanofi SA - Key offerings
Exhibit 167: Sanofi SA - Segment focus
12.15 TerSera Therapeutics LLC
Exhibit 168: TerSera Therapeutics LLC - Overview
Exhibit 169: TerSera Therapeutics LLC - Product / Service
Exhibit 170: TerSera Therapeutics LLC - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 171: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 172: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 173: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 174: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 175: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Viatris Inc.
Exhibit 176: Viatris Inc. - Overview
Exhibit 177: Viatris Inc. - Business segments
Exhibit 178: Viatris Inc. - Key news
Exhibit 179: Viatris Inc. - Key offerings
Exhibit 180: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 181: Inclusions checklist
Exhibit 182: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 183: Currency conversion rates for US$
13.4 Research methodology
Exhibit 184: Research methodology
Exhibit 185: Validation techniques employed for market sizing
Exhibit 186: Information sources
13.5 List of abbreviations
Exhibit 187: List of abbreviations